Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases

Obregon, 2017, Update on dendritic cell-induced immunological and clinical tolerance, Front. Immunol., 8, 1514, 10.3389/fimmu.2017.01514 Nagai, 2019, The CD28–B7 family of co-signaling molecules, Adv. Exp. Med. Biol., 1189, 25, 10.1007/978-981-32-9717-3_2 Jiang, 2020, Progress and challenges in precise treatment of tumors with PD-1/PD-L1 blockade, Front. Immunol., 11, 339, 10.3389/fimmu.2020.00339 Sun, 2020, Targeting glycosylated PD-1 induces potent anti-tumor immunity, Canc. Res., 2298, 10.1158/0008-5472.CAN-19-3133 Topalian, 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Curr. Opin. Immunol., 24, 207, 10.1016/j.coi.2011.12.009 Chen, 2019, Mechanisms regulating PD-L1 expression on tumor and immune cells, J. Immunother. Cancer, 7, 305, 10.1186/s40425-019-0770-2 Zamani, 2016, PD-1/PD-L and autoimmunity: a growing relationship, Cell. Immunol., 310, 27, 10.1016/j.cellimm.2016.09.009 Fife, 2011, The role of the PD-1 pathway in autoimmunity and peripheral tolerance, Ann. N. Y. Acad. Sci., 1217, 45, 10.1111/j.1749-6632.2010.05919.x Pedoeem, 2014, Programmed death-1 pathway in cancer and autoimmunity, Clin. Immunol., 153, 145, 10.1016/j.clim.2014.04.010 Kivisäkk, 2019, Co-signaling molecules in neurological diseases, Adv. Exp. Med. Biol., 1189, 233, 10.1007/978-981-32-9717-3_9 Gonsette, 2012, Self-tolerance in multiple sclerosis, Acta Neurol. Belg., 112, 133, 10.1007/s13760-012-0061-x Joller, 2012, Immune checkpoints in central nervous system autoimmunity, Immunol. Rev., 248, 122, 10.1111/j.1600-065X.2012.01136.x Kroner, 2005, A PD-1 polymorphism is associated with disease progression in multiple sclerosis, Ann. Neurol., 58, 50, 10.1002/ana.20514 Pawlak-Adamska, 2017, PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS, J. Neuroimmunol., 305, 115, 10.1016/j.jneuroim.2017.02.006 Salmaninejad, 2018, PD-1 and cancer: molecular mechanisms and polymorphisms, Immunogenetics, 70, 73, 10.1007/s00251-017-1015-5 Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu. Rev. Immunol., 26, 677, 10.1146/annurev.immunol.26.021607.090331 Lin, 2020, Progress in PD-1/PD-L1 pathway inhibitors: from biomacromolecules to small molecules, Eur. J. Med. Chem., 186, 111876, 10.1016/j.ejmech.2019.111876 Zhu, 2017, Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer, Oncotarget, 8, 97671, 10.18632/oncotarget.18311 Liu, 2015, Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways, Arthritis Res. Ther., 17, 340, 10.1186/s13075-015-0859-z Wu, 2009, Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia, Immunol, Invest, 38, 408 Bommarito, 2017, Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1, Clin. Exp. Immunol., 188, 455, 10.1111/cei.12949 Philips, 2020, The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals, J. Biol. Chem., 295, 4372, 10.1074/jbc.AC119.011747 Man, 2017, Transcription factor IRF4 promotes CD8+ T cell exhaustion and limits the development of memory-like T cells during chronic infection, Immunity, 47, 1129, 10.1016/j.immuni.2017.11.021 Azuma, 2019, Co-signal molecules in T-Cell Activation: historical overview and perspective, Adv. Exp. Med. Biol., 1189, 3, 10.1007/978-981-32-9717-3_1 Taylor, 2016, Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of Co-receptor PD-to enhance CD8+ cytolytic T cell responses, Immunity, 44, 274, 10.1016/j.immuni.2016.01.018 Terawaki, 2011, IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity, J. Immunol., 186, 2772, 10.4049/jimmunol.1003208 Maeda, 2019, Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells, J. Biol. Chem., 294, 10.1074/jbc.RA119.010379 Wang, 2017, The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint, Int. J. Mol. Sci., 18, 2540, 10.3390/ijms18122540 Redd, 2018, H3K4me3 mediates the NF-κB p50 homodimer binding to the pdcd1 promoter to activate PD-1 transcription in T cells, OncoImmunology, 7, 10.1080/2162402X.2018.1483302 Bally, 2020, PD-1 expression during acute infection is repressed through an LSD1–blimp-1 Axis, J. Immunol., 204, 449, 10.4049/jimmunol.1900601 Röver, 2018, PD-1 (PDCD1) promoter methylation is a prognostic factor in patients with diffuse lower-grade gliomas harboring isocitrate dehydrogenase (IDH) mutations, EBioMedicine, 28, 97, 10.1016/j.ebiom.2018.01.016 Ørskov, 2015, Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: a rationale for combined targeting of PD-1 and DNA methylation, Oncotarget, 6, 9612, 10.18632/oncotarget.3324 Garcia-Diaz, 2017, Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression, Cell Rep., 19, 1189, 10.1016/j.celrep.2017.04.031 Qin, 2020, NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer, Nat. Commun., 11, 1669, 10.1038/s41467-020-15364-z Yan, 2020, Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC ) cells, Cancer Immunol, Immunotherapy, 1, 1891 Yoyen-Ermis, 2019, Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS, Sci. Rep., 9, 11697, 10.1038/s41598-019-48256-4 Peng, 2019, BCL6-Mediated silencing of PD-1 ligands in germinal center B cells maintains follicular T cell population, J. Immunol., 202, 704, 10.4049/jimmunol.1800876 Woods, 2015, HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade, Cancer Immunol. Res., 3, 1375, 10.1158/2326-6066.CIR-15-0077-T Lv, 2020, PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer, Oncol. Lett., 19, 1223 Zhu, 2020, Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma, Int. Immunopharm., 82, 106245, 10.1016/j.intimp.2020.106245 Schonfeld, 2020, The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma, J. Biol. Chem., 295, 7126, 10.1074/jbc.RA120.013401 Xu, 2020, Long noncoding RNAs control the modulation of immune checkpoint molecules in cancer, Cancer Immunol. Res., 8, 937, 10.1158/2326-6066.CIR-19-0696 Franchini, 2019, Microtubule-driven stress granule dynamics regulate inhibitory immune checkpoint expression in T cells, Cell Rep., 26, 94, 10.1016/j.celrep.2018.12.014 Rafiq, 2019, A mechano-signalling network linking microtubules, myosin IIA filaments and integrin-based adhesions, Nat. Mater., 18, 638, 10.1038/s41563-019-0371-y Okada, 2017, Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells, cell rep, 20, 1017, 10.1016/j.celrep.2017.07.027 Pentcheva-Hoang, 2007, Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability, Proc. Natl. Acad. Sci. U.S.A., 104, 17765, 10.1073/pnas.0708767104 Meng, 2018, FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells, Nature, 564, 130, 10.1038/s41586-018-0756-0 Lyle, 2019, c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth, Sci. Rep., 9, 20257, 10.1038/s41598-019-56208-1 Hsu, 2018, Posttranslational modifications of PD-L1 and their applications in cancer therapy, Canc. Res., 78, 6349, 10.1158/0008-5472.CAN-18-1892 Wang, 2019, Autophagy inhibition enhances PD-L1 expression in gastric cancer, J. Exp. Clin. Canc. Res., 38, 140, 10.1186/s13046-019-1148-5 Yao, 2019, Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours, Nat. Biomed. Eng., 3, 306, 10.1038/s41551-019-0375-6 Su, 2020, EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma, Mol. Carcinog., 59, 520, 10.1002/mc.23176 Wang, 2019, HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity, Nat. Chem. Biol., 15, 42, 10.1038/s41589-018-0161-x Frigola, 2011, Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma, Clin. Canc. Res., 17, 1915, 10.1158/1078-0432.CCR-10-0250 Xavier Frigola, 2012, Soluble B7-H1: differences in production between dendritic cells and T cells, Immunol, Letture, 23, 78 Jang, 2015, Imaging of cell–cell communication in a vertical orientation reveals high-resolution structure of immunological synapse and novel PD-1 dynamics, J. Immunol., 195, 1320, 10.4049/jimmunol.1403143 Saito, 2019, Molecular dynamics of co-signal molecules in T-cell activation, Adv. Exp. Med. Biol., 1189, 135, 10.1007/978-981-32-9717-3_5 Fife, 2009, Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal, Nat. Immunol., 10, 1185, 10.1038/ni.1790 Hui, 2017, T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition, Science, 355, 1428, 10.1126/science.aaf1292 Sugiura, 2019, Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses, Science, 364, 558, 10.1126/science.aav7062 Saeidi, 2018, T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses, Front. Immunol., 9, 2569, 10.3389/fimmu.2018.02569 Liu, 2020, PD-1-Mediated PI3K/Akt/mTOR, caspase 9/caspase 3 and ERK pathways are involved in regulating the apoptosis and proliferation of CD4+ and CD8+ T cells during BVDV infection in vitro, Front. Immunol., 11, 467, 10.3389/fimmu.2020.00467 Patsoukis, 2015, PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation, Nat. Commun., 6, 6692, 10.1038/ncomms7692 Latchman, 2004, PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells, Proc. Natl. Acad. Sci. U.S.A., 101, 10691, 10.1073/pnas.0307252101 Probst, 2005, Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4, Nat. Immunol., 6, 280, 10.1038/ni1165 Wang, 2008, Programmed death 1 ligand signaling regulates the generation of adaptative Foxp3+CD4+ regulatory T Cells, Proc. Natl. Acad. Sci. U.S.A., 105, 9331, 10.1073/pnas.0710441105 Francisco, 2009, PD-L1 regulates the development, maintenance, and function of induced regulatory T cells, J. Exp. Med., 206, 3015, 10.1084/jem.20090847 Sambucci, 2018, FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis, Sci. Rep., 8, 363674, 10.1038/s41598-018-21861-5 Amarnath, 2011, The PDL1-PD1 Axis converts human Th1 cells into regulatory T cells, Immunology, 3, 111 Stathopoulou, 2018, PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells, Immunity, 49, 247, 10.1016/j.immuni.2018.05.006 Ransohoff, 2015, Multiple sclerosis - a quiet revolution, Nature, 11, 134 Walton, 2020, Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition, Mult. Scler. J., 26, 1816, 10.1177/1352458520970841 Confavreux, 2014, The clinical course of multiple sclerosis, Handb. Clin. Neurol., 122, 343, 10.1016/B978-0-444-52001-2.00014-5 Mahad, 2015, Pathological mechanisms in progressive multiple sclerosis, Lancet Neurol., 14, 183, 10.1016/S1474-4422(14)70256-X Grigoriadis, 2015, A basic overview of multiple sclerosis immunopathology, Eur. J. Neurol., 22, 3, 10.1111/ene.12798 Javan, 2016, Downregulation of immunosuppressive molecules, PD-1 and PD-L1 but not PD-L2, in the patients with multiple sclerosis, Iran J Allergy Asthma Immunol., 15, 296 Trabattoni, 2009, Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease, J. Immunol., 183, 4984, 10.4049/jimmunol.0901038 George, 2012, Pharmacology and therapeutic potential of interferons, Pharmacol. Ther., 135, 44, 10.1016/j.pharmthera.2012.03.006 Feng, 2019, Interferon-β corrects massive gene dysregulation in multiple sclerosis: short-term and long-term effects on immune regulation and neuroprotection, EBioMedicine, 49, 269, 10.1016/j.ebiom.2019.09.059 Schreiner, 2004, Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis, J. Neuroimmunol., 155, 172, 10.1016/j.jneuroim.2004.06.013 Wiesemann, 2008, Effects of interferon-β on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-β treatment in patients with multiple sclerosis, Mult. Scler., 14, 166, 10.1177/1352458507081342 Pittet, 2011, The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells, Glia, 59, 841, 10.1002/glia.21158 Ortler, 2008, B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis, Eur. J. Immunol., 38, 1734, 10.1002/eji.200738071 Pittet, 2011, Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis, J. Neuroinflammation, 8, 155, 10.1186/1742-2094-8-155 Lovett-Racke, 2017, Contribution of EAE to understanding and treating multiple sclerosis, J. Neuroimmunol., 304, 40, 10.1016/j.jneuroim.2016.08.013 Robinson, 2014, The experimental autoimmune encephalomyelitis (EAE) model of MS. utility for understanding disease pathophysiology and treatment, Handb. Clin. Neurol., 122, 173, 10.1016/B978-0-444-52001-2.00008-X Kroner, 2009, Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants, Am. J. Pathol., 174, 2290, 10.2353/ajpath.2009.081012 Zhu, 2006, Differential role of programmed death-ligand 1 and programmed death-ligand 2 in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis, J. Immunol., 176, 3480, 10.4049/jimmunol.176.6.3480 Magnus, 2005, Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS, J. Neurosci., 25, 2537, 10.1523/JNEUROSCI.4794-04.2005 Salama, 2003, Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis, J. Exp. Med., 198, 71, 10.1084/jem.20022119 Schreiner, 2008, PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE, Eur. J. Immunol., 38, 2706, 10.1002/eji.200838137 Carter, 2007, PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis, J. Neuroimmunol., 182, 124, 10.1016/j.jneuroim.2006.10.006 Hu, 2016, Programmed death ligand-1 on microglia regulates Th1 differentiation via nitric oxide in experimental autoimmune encephalomyelitis, Neurosci. Bull., 32, 70, 10.1007/s12264-015-0010-9 Chunhe Wang, 2010, Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis, J. Neurosci., 88, 7 Yogev, 2012, Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor+ regulatory T cells, Immunity, 37, 264, 10.1016/j.immuni.2012.05.025 Hirata, 2005, Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand, J. Immunol., 174, 1888, 10.4049/jimmunol.174.4.1888 Gold, 2009, Estrogen treatment in multiple sclerosis, J. Neurol. Sci., 286, 99, 10.1016/j.jns.2009.05.028 Wang, 2009, Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1, Immunology, 126, 329, 10.1111/j.1365-2567.2008.03051.x Bodhankar, 2013, PD-1 interaction with PD-L1 but not PD-L2 on B-cells mediates protective effects of estrogen against EAE, J. Clin. Cell. Immunol., 143 Seifert, 2019, Estrogen-induced compensatory mechanisms protect IL-10-deficient mice from developing EAE, J. Neuroinflammation, 16, 195, 10.1186/s12974-019-1588-z Cao, 2020, The change of PD1, PDL1 in experimental autoimmune encephalomyelitis treated by 1,25(OH)2D3, J. Neuroimmunol., 338, 577079, 10.1016/j.jneuroim.2019.577079 Bin Chang, 2020, Dendritic cell upregulation of programmed death ligand-1 via DNA demethylation inhibits experimental autoimmune encephalomyelitis, J. Autoimmun., 107, 102362, 10.1016/j.jaut.2019.102362 Ottum, 2015, Opposing roles of interferon-gamma on cells of the central nervous system in autoimmune neuroinflammation, Front. Immunol., 6, 539, 10.3389/fimmu.2015.00539 Arellano, 2015, Stage-specific role of interferon-gamma in experimental autoimmune encephalomyelitis and multiple sclerosis, Front. Immunol., 6, 492, 10.3389/fimmu.2015.00492 Cheng, 2007, vol. 185, 75 White, 2018, Innate IFN-γ ameliorates experimental autoimmune encephalomyelitis and promotes myeloid expansion and PDL-1 expression, Sci. Rep., 8, 259, 10.1038/s41598-017-18543-z Sun, 2019, The PD-1/PD-Ls pathway is up-regulated during the suppression of experimental autoimmune encephalomyelitis treated by Astragalus polysaccharides, J. Neuroimmunol., 332, 78, 10.1016/j.jneuroim.2019.03.019 Li, 2020, Characterization and anti-tumor bioactivity of astragalus polysaccharides by immunomodulation, Int. J. Biol. Macromol., 145, 985, 10.1016/j.ijbiomac.2019.09.189 Tangye, 2013, The good, the bad and the ugly - TFH cells in human health and disease, Nat. Rev. Immunol., 13, 412, 10.1038/nri3447 Good-Jacobson, 2010, PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells, Nat. Immunol., 11, 535, 10.1038/ni.1877 He, 2013, Circulating precursor CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure, Immunity, 39, 770, 10.1016/j.immuni.2013.09.007 Magliozzi, 2007, Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology, Brain, 130, 1089, 10.1093/brain/awm038 Guo, 2018, T follicular helper-like cells are involved in the pathogenesis of experimental autoimmune encephalomyelitis, Front. Immunol., 9, 944, 10.3389/fimmu.2018.00944 Quinn, 2018, Role of TFH cells in promoting T Helper 17-induced neuroinflammation, Front. Immunol., 9, 382, 10.3389/fimmu.2018.00382 Fan, 2015, Follicular helper CD4+ T cells in human neuroautoimmune diseases and their animal models, Mediat. Inflamm., 638968 Bertsias, 2009, Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus, Arthritis Rheum., 60, 207, 10.1002/art.24227 Gao, 2017, Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus erythematosus risk, Oncotarget, 8, 36885, 10.18632/oncotarget.16378 Nielsen, 2003, Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes, Tissue Antigens, 62, 492, 10.1046/j.1399-0039.2003.00136.x Liu, 2014, A promoter region polymorphism in PDCD-1 gene is associated with risk of rheumatoid arthritis in the Han Chinese population of southeastern China, Int. J. Genomics. 2014, 247637 Kong, 2005, A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese, Arthritis Rheum., 52, 1058, 10.1002/art.20966 Lee, 2006, Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population, Arthritis Res. Ther., 8, R136, 10.1186/ar2071 Yang, 2011, Association of polymorphisms in the programmed cell death 1 (PD-1) and PD-1 ligand genes with ankylosing spondylitis in a Chinese population, Clin. Exp. Rheumatol., 29, 13 Yang, 2015, The programmed cell death 1 gene polymorphisms (PD 1.3 G/A, PD 1.5 C/T and PD 1.9 C/T) and susceptibility to ankylosing spondylitis: a meta-analysis, J. Orthop. Sci., 20, 55, 10.1007/s00776-014-0648-6 Qian, 2018, Association of PD-1 and PD-L1 genetic polymorphyisms with type 1 diabetes susceptibility, J. Diabetes Res., 1614683 Hayashi, 2008, Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients, Eur. J. Endocrinol., 158, 817, 10.1530/EJE-07-0649 Mitchell, 2009, Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison’s disease and Graves’ disease susceptibility, J. Clin. Endocrinol. Metab., 94, 5139, 10.1210/jc.2009-1404 Wang, 2007, Polymorphisms of genes for programmed cell death 1 ligands in patients with rheumatoid arthritis, J. Clin. Immunol., 27, 563, 10.1007/s10875-007-9113-z Wang, 2007, Ligands for programmed cell death 1 gene in patients with systemic lupus erythematosus, J. Rheumatol., 34, 721 Liu, 2009, Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus, J. Biomed. Biotechnol., 406136 Luo, 2018, Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis, Mol. Med. Rep., 17, 3297 Kanai, 2003, Blockade of B7-H1 suppresses the development of chronic intestinal inflammation, J. Immunol., 171, 4156, 10.4049/jimmunol.171.8.4156 Legány, 2017, The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren’s syndrome and systemic sclerosis, Immunol. Res., 65, 622, 10.1007/s12026-016-8880-0 Tsutsumi, 2006, Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes, Diabet. Med., 23, 1145, 10.1111/j.1464-5491.2006.01951.x Li, 2020, PD-1 and PD-L1 expression in peripheral CD4/CD8+ T cells is restored in the partial remission phase in type 1 diabetes, J Clin Endocrinol Metab, 105, dgaa130, 10.1210/clinem/dgaa130 Granados, 2017, Programmed cell death-1, PD-1, is dysregulated in T cells from children with new onset type 1 diabetes, PloS One, 12, 10.1371/journal.pone.0183887 Luo, 2016, PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus, Arthritis Res. Ther., 18, 47, 10.1186/s13075-016-0942-0 Zhao, 2020, Low expressions of PD-L1 and CTLA-4 by induced CD4+CD25+ Foxp3+ Tregs in patients with SLE and their correlation with the disease activity, Cytokine, 133, 155119, 10.1016/j.cyto.2020.155119 Mozaffarian, 2008, Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1, Rheumatology, 47, 1335, 10.1093/rheumatology/ken256 Wan, 2006, Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis, J. Immunol., 177, 8844, 10.4049/jimmunol.177.12.8844 Floudas, 2020, Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint, JCI Insight, 5, 10.1172/jci.insight.139032 Moret, 2014, Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions, Arthritis Res. Ther., 16, 497, 10.1186/s13075-014-0497-x Kobayashi, 2005, Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren’s syndrome, J. Rheumatol., 32, 2156 Mataki, 2007, Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases, Am. J. Gastroenterol., 102, 302, 10.1111/j.1572-0241.2006.00948.x Oikawa, 2007, Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease, Pathol. Int., 57, 485, 10.1111/j.1440-1827.2007.02129.x Agina, 2019, Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response, Clin. Exp. Hepatol., 5, 256, 10.5114/ceh.2019.87642 Nishimura, 1998, Immunological studies on PD-1-deficient mice: implication of PD-1 as a negative regulator for B cell responses, Int. Immunol., 10, 1563, 10.1093/intimm/10.10.1563 Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 11, 141, 10.1016/S1074-7613(00)80089-8 Tanaka, 2001, Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice, Science, 291, 319, 10.1126/science.291.5502.319 Keir, 2006, Tissue expression of PD-L1 mediates peripheral T cell tolerance, J. Exp. Med., 203, 883, 10.1084/jem.20051776 Raptopoulou, 2010, The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis, Arthritis Rheum., 62, 1870, 10.1002/art.27500 Dong, 2004, B7-H1 determines accumulation and deletion of intrahepatic CD8+ T lymphocytes, Immunity, 20, 327, 10.1016/S1074-7613(04)00050-0 Lucas, 2008, Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice, J. Immunol., 181, 2513, 10.4049/jimmunol.181.4.2513 Wang, 2010, PD-1 deficiency results in the development of fatal myocarditis in MRL mice, Int. Immunol., 22, 443, 10.1093/intimm/dxq026 Li, 2021, Programmed death-ligand 2 deficiency exacerbates experimental autoimmune myocarditis in mice, Int. J. Mol. Sci., 22, 1426, 10.3390/ijms22031426 Ansari, 2003, The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice, J. Exp. Med., 198, 63, 10.1084/jem.20022125 Kasagi, 2010, Anti-Programmed cell death 1 antibody reduces CD4+ PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice, J. Immunol., 184, 2337, 10.4049/jimmunol.0901652 Wong, 2013, Blockade of programmed death-1 in young (New Zealand black × New Zealand white)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease, J. Immunol., 190, 5402, 10.4049/jimmunol.1202382 Ding, 2006, Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice, Clin. Immunol., 118, 258, 10.1016/j.clim.2005.10.017 Song, 2015, Protective effects of Fc-fused PD-L1 on two different animal models of colitis, Gut, 64, 260, 10.1136/gutjnl-2014-307311 El Khatib, 2015, β-cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection, Gene Ther., 22, 430, 10.1038/gt.2015.18 Ben Nasr, 2017, PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes, Sci. Transl. Med., 9, 10.1126/scitranslmed.aam7543 Zhang, 2020, Engineered PD-L1-expressing platelets reverse new-onset type 1 diabetes, Adv. Mater., 32 Simpson, 2010, Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus, Arthritis Rheum., 62, 234, 10.1002/art.25032 Wang, 2013, High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis, Clin. Exp. Immunol., 174, 212, 10.1111/cei.12162 Szabo, 2013, Follicular helper T cells may play an important role in the severity of primary Sjögren’s syndrome, Clin. Immunol., 147, 95, 10.1016/j.clim.2013.02.024 yi Li, 2012, Role of the frequency of blood CD4+ CXCR5+ CCR6+ T cells in autoimmunity in patients with Sjögren’s syndrome, Biochem. Biophys. Res. Commun., 422, 238, 10.1016/j.bbrc.2012.04.133 Viisanen, 2017, Circulating CXCR5+PD-1+ICOS+ Follicular T helper cells are increased close to the diagnosis of type 1 diabetes in children with multiple autoantibodies, Diabetes, 66, 437, 10.2337/db16-0714 Liu, 2018, Constitutive changes in circulating follicular helper T cells and their subsets in patients with graves disease, J. Immunol. Res., 7 Zhao, 2018, Increased circulating Tfh17 and PD-1+ Tfh cells are associated with autoantibodies in Hashimoto’s thyroiditis, Autoimmunity, 51, 352, 10.1080/08916934.2018.1516761 Luo, 2013, Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis, J. Neuroimmunol., 256, 55, 10.1016/j.jneuroim.2012.12.001 Li, 2015, Association of circulating follicular helper T cells with disease course of NMO spectrum disorders, J. Neuroimmunol., 278, 239, 10.1016/j.jneuroim.2014.11.011 Szabo, 2014, The histopathology of labial salivary glands in primary sjögren’s syndrome: focusing on follicular helper T cells in the inflammatory infiltrates, Mediat. Inflamm., 631787 Szabó, 2016, A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren’s syndrome and systemic lupus erythematosus, Clin. Exp. Immunol., 183, 76, 10.1111/cei.12703 Brokstad, 2018, T follicular-like helper cells in the peripheral blood of patients with primary Sjögren’s syndrome, Scand. J. Immunol., 88, 10.1111/sji.12679 Rao, 2017, Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis, Nature, 542, 110, 10.1038/nature20810 Ekman, 2019, Circulating CXCR5−PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes, Diabetologia, 62, 1681, 10.1007/s00125-019-4936-8 Bocharnikov, 2019, PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21, JCI Insight, 4, 10.1172/jci.insight.130062 Huang, 2019, Membrane-associated epithelial cell adhesion molecule is slowly cleaved by -secretase prior to efficient proteasomal degradation of its intracellular domain, J. Biol. Chem., 294, 3051, 10.1074/jbc.RA118.005874 Sherman, 2020, Proteasome inhibitors: harnessing proteostasis to combat disease, Molecules, 25, 671, 10.3390/molecules25030671 Macleod, 2015, The role and therapeutic targeting of α-, β-and γ-secretase in Alzheimer's disease, Futur. Sci. OA., 1, FSO11, 10.4155/fso.15.9